- Home
- INSW vs IMCR Comparison
INSW vs IMCR Comparison
Compare INSW & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- IMCR
- Stock Information
- Founded
- INSW 1999
- IMCR 2008
- Country
- INSW United States
- IMCR United Kingdom
- Employees
- INSW N/A
- IMCR N/A
- Industry
- INSW Semiconductors
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSW Technology
- IMCR Health Care
- Exchange
- INSW Nasdaq
- IMCR Nasdaq
- Market Cap
- INSW 1.7B
- IMCR 1.4B
- IPO Year
- INSW N/A
- IMCR 2021
- Fundamental
- Price
- INSW $33.09
- IMCR $29.67
- Analyst Decision
- INSW Strong Buy
- IMCR Buy
- Analyst Count
- INSW 3
- IMCR 12
- Target Price
- INSW $60.00
- IMCR $63.00
- AVG Volume (30 Days)
- INSW 823.2K
- IMCR 372.2K
- Earning Date
- INSW 05-07-2025
- IMCR 05-07-2025
- Dividend Yield
- INSW 15.52%
- IMCR N/A
- EPS Growth
- INSW N/A
- IMCR N/A
- EPS
- INSW 8.38
- IMCR N/A
- Revenue
- INSW $951,613,000.00
- IMCR $310,202,000.00
- Revenue This Year
- INSW N/A
- IMCR $18.97
- Revenue Next Year
- INSW $2.65
- IMCR $8.43
- P/E Ratio
- INSW $3.96
- IMCR N/A
- Revenue Growth
- INSW N/A
- IMCR 24.36
- 52 Week Low
- INSW $31.70
- IMCR $27.19
- 52 Week High
- INSW $65.94
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- INSW 41.01
- IMCR 50.47
- Support Level
- INSW $33.56
- IMCR $28.92
- Resistance Level
- INSW $34.92
- IMCR $30.50
- Average True Range (ATR)
- INSW 1.10
- IMCR 1.44
- MACD
- INSW 0.03
- IMCR 0.09
- Stochastic Oscillator
- INSW 26.56
- IMCR 46.17
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.